These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 2564435)

  • 21. Age at onset and gender of schizophrenic patients in relation to neuroleptic resistance.
    Meltzer HY; Rabinowitz J; Lee MA; Cola PA; Ranjan R; Findling RL; Thompson PA
    Am J Psychiatry; 1997 Apr; 154(4):475-82. PubMed ID: 9090333
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Neuroleptic induced deficit syndrome].
    Szafrański T
    Psychiatr Pol; 1995; 29(3):359-69. PubMed ID: 7652089
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Neuroleptic modification of basic schizophrenic disorders].
    Heim M; Morgner J
    Psychiatr Neurol Med Psychol (Leipz); 1987 May; 39(5):274-80. PubMed ID: 2888144
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Electroencephalography in schizophrenic patients: comparison between neuroleptic-naive state and after treatment.
    Nagase Y; Okubo Y; Toru M
    Biol Psychiatry; 1996 Sep; 40(6):452-6. PubMed ID: 8879464
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Survey of the adjuvant use of benzodiazepines for treating outpatients with schizophrenia.
    Pecknold JC
    J Psychiatry Neurosci; 1993 Mar; 18(2):82-4. PubMed ID: 8096393
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [New chemotherapy approaches to psychoses].
    Olié JP; Baylé FJ
    Encephale; 1997 Apr; 23 Spec No 2():2-9. PubMed ID: 9273302
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Evaluation trial on the efficacy of neuroleptics on the outcome of schizophrenia].
    Dollfus S; Petit M
    Encephale; 1991; 17(4):247-53. PubMed ID: 1683625
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Possible predictors of neuroleptic-resistant schizophrenic relapse: influence of negative symptoms and acute extrapyramidal side effects.
    Kinon BJ; Kane JM; Chakos M; Munne R
    Psychopharmacol Bull; 1993; 29(3):365-9. PubMed ID: 7907184
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Schizophrenia and addiction: An evaluation of the self-medication hypothesis].
    Potvin S; Stip E; Roy JY
    Encephale; 2003; 29(3 Pt 1):193-203. PubMed ID: 12876543
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Tolerance of neuroleptics, deficit syndrome and cognitive functions].
    Kahn JP
    Encephale; 1996 Jun; 22 Spec No 2():49-54. PubMed ID: 8767043
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Discontinuation of neuroleptics in chronic schizophrenics. I. Summary of the literature].
    Woggon B
    Int Pharmacopsychiatry; 1979; 14(1):34-56. PubMed ID: 39040
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Negative and deficit symptoms in schizophrenia do respond to neuroleptics.
    Goldberg SC
    Schizophr Bull; 1985; 11(3):453-6. PubMed ID: 2863872
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [The effect of neuroleptics in a attempt at understanding the vulnerability to schizophrenia].
    Meurice E
    Acta Psychiatr Belg; 1992; 92(6):339-54. PubMed ID: 1364282
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of neuroleptic medications on the cognition of patients with schizophrenia: a review of recent studies.
    Goldberg TE; Weinberger DR
    J Clin Psychiatry; 1996; 57 Suppl 9():62-5. PubMed ID: 8823353
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Self-reported prescribing practices for schizophrenic patients among Israeli psychiatrists.
    Heresco-Levy U; Brom D; Greenberg D
    Isr J Psychiatry Relat Sci; 1993; 30(3):164-74. PubMed ID: 7901179
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Depot neuroleptic therapy: clinical considerations.
    Remington GJ; Adams ME
    Can J Psychiatry; 1995 Apr; 40(3 Suppl 1):S5-11. PubMed ID: 7627927
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neuroleptic treatment of negative symptoms in schizophrenic patients. Efficacy problems and methodological difficulties.
    Möller HJ
    Eur Neuropsychopharmacol; 1993 Mar; 3(1):1-11. PubMed ID: 8097126
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The efficacy of piquindone, a new atypical neuroleptic, in the treatment of the positive and negative symptoms of schizophrenia.
    Cohen JD; Van Putten T; Marder S; Berger PA; Stahl SM
    J Clin Psychopharmacol; 1987 Oct; 7(5):324-9. PubMed ID: 2890671
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Tardive dyskinesia induced by classical antipsychotic drugs: a Tunisian sample of schizophrenics].
    Sejil I; Oumaya A; Bouguerra C; Mehdi F; Bellaaj R; Gallali S
    Encephale; 2013 May; 39 Suppl 1():S36-41. PubMed ID: 23219594
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Problems in classification of schizophrenics as neuroleptic responders and nonresponders.
    Csernansky JG; Kaplan J; Hollister LE
    J Nerv Ment Dis; 1985 Jun; 173(6):325-31. PubMed ID: 2860202
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.